

ABSTRACT

Company name [ATLASense Biomed Ltd.](https://www.atlasensebiomed.com) * Website <https://www.atlasensebiomed.com> *

CEO name [Tal Or](#) *

CATEGORY: [Medical Devices](#) *

SESSIONS [Hospital at home: universities 'and hospitals' innovations](#)

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Unlike expensive, single-use wearables, REPHAEL is a reusable, ICU-grade system. It continuously monitors chronically ill patients for co-morbidities at home and in hospitals. This award-winning technology from ATLASense enables proactive care through a unique subscription model.

ATLASense has already partnered with Henry Ford Health System (USA), Hadassah Medical Center, and Assuta Ashdod (Israel), AM Diagnostics, and Medinat (Europe).

o Core Technology What is the technology, its uniqueness, and its value proposition?

REPHAEL's secret lies in its multifunctional platform. A reusable PolyMonitor captures 16 vital signs simultaneously, sending them to our cloud. There, our AI software analyzes them, identifying early warning biomarkers for over 50 clinical applications. This unlocks a wealth of medical insights, empowering proactive healthcare decisions.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

With its validated platform, REPHAEL has powered the development and testing of 18 out of 50+ potential clinical applications. ATLASense is pursuing FDA, CE, and AMAR approvals while securing early traction with 3 commercial agreements already signed.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

REPHAEL's ease of use simplifies deployment, allowing ATLASense to partner with distributors who meet specific business goals. Initial deals with just two distributors guarantee over \$60 million by 2028 through commercial implementations following regulatory approvals. Before then, paid pilot programs with these same distributors are already generating revenue for ATLASense.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

R&D:

- **Evolving Tech:** New PolyMonitors models with more sensors & Telemetry-In-The-Pocket app for on-the-go access.
- **Advanced Analytics:** Powerful cloud-based AI analyzes unique data, unlocks unique clinical indicators & real-time predictive insights.
- **Rigorous Validation:** All indicators validated through the paid pilots.

Financial:

- **Explosive Growth:** Projected YoY growth of over 1,200%.
- **Strategic Funding:** Raising \$10M to fuel our ambitious plans.